Burns, J.   A clinical approach to sports-related eye injuries.  San Antonio Medicine 56 (3): 35-37 2003.

 

Somaiya MD, Burns JD, Mintz R, et al. Factors affecting visual outcomes following small-incision phacoemulsification in diabetic patients.  J Cataract Refract Surg 28(12): 1364-1371 2002.

                                                                                     

Burns JD, Jenkins FP, Muller LT, et al. Unilateral mydriasis associated  with exposure to flea spray. Arch Ophthalmol. 120(5): 665 2002.

 

Burns J. Student membership: Recruitment issues affecting an underutilized resource.  Missouri Medicine.  94(11): 647 1997.

 

Howell N, Halvorson S, Burns J, et al. When does bilateral optic atrophy become Leber hereditary optic neuropathy? Am J Human Genetics. 53(4): 959-963 1993.

 

Safety and Efficacy of 1% AL-37807 Ophthalmic Suspension in Patients with Open-Angle Glaucoma or Ocular Hypertension

 

A One-Week Comfort Study of BID Dosed Brinzolamide 1.0%/Timolol 0.5% Ophthalmic Suspension Compared to BID Dosed COSOPT® in Patients with Open-Angle Glaucoma or Ocular Hypertension

 

A Study to Asess the Safety and Efficacy of AL-37807 Ophthalmic Suspension Compared to Xalatan, Timolol, and Vehicle in Patients with Open-Angle Glaucoma or Ocular Hypertension

 

Comparison of Safety and Efficacy of Brinzolamide/Timolol Fixed Combination vs COSOPT® IN Patients with Open-Angle Glaucoma or Ocular Hypertension

 

A Multicenter, Double-Masked, Randomized, Parallel, Active-Controlled Three Month Study (Plus 9-Month, Masked Extension) Of The Safety and Efficacy of Bimatoprost Ophthalmic Solution 0.0125% Once-Daily Compared to Lumigan® (Bimatoprost Ophthalmic Solution) 0.03% Once-Daily In Patients With Glaucoma or Ocular Hypertension

 

FVF3689g:  A Phase IIIB, Single-Masked, Multicenter, Randomized Study to Evaluate the Safety and Tolerability of Ranibizumab in Naïve and Previously Treated Subjects with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)  October 2005—Present

 

A 3 year, Phase III, Multi-Center, Masked, Randomized, Sham-Controlled Trial to Assess the Safety and Efficacy of 700µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Diabetic Macular Edema.  Sub-Investigator-- June 2005 --Present

 

EOP1013:  A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Dose-Finding Trial, in Parallel Groups, to Compare the Safety and Efficacy of Intravitreous Injections of 0.3, 0.03, or 0.003 mg Pegaptanib Sodium (Macugen), Given as Often as Every 6 weeks for 3 Years, to Sham Injections, in Subjects with Diabetic Macular Edema (DME) Involving the Center of the Macula   March 06- Present

 

FVF3426g:  An Open-label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects with Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) Who Have Completed the Treatment Phase of a Genentech-Sponsored Ranibizumab  June 2005-Present

 

AGN 206207-011:  A 3 year, Phase III, Multi-Center, Masked, Randomized, Sham-Controlled Trial to Assess the Safety and Efficacy of 700µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Diabetic Macular Edema   May 2005-Present

 

AGN 206207-008:  A Six-Month Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS Applicator System) in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion

March 2005- Present

 

A Six Month Phase 3, Multi-center, Masked, Randomized, Sham-controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficcy of 700 μg and 350 μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS Applicator System) in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion.  Sub-Investigator-- March 2005--Present

 

EOP1009:  A Phase II Prospective, Randomized, Double-Masked, Sham-Controlled, Dose-Ranging, Multicenter Trial to Assess the Effect of pegaptanib sodium on Foveal Thickening in Patients with Exudative Subfoveal Age-Related Macular Degeneration.

 

VisTA Trial:  A Randomized, Single-Masked, Multicenter, Phase II Evaluation of the Effect of Photodynamic Therapy Using Verteporfin (Visudyne Therapy) in Combination with Intravitreal Injection of either 0mg, 1mg or 4mg of Triamcinolone Acetonide in Occult Subfoveal and Minimally Classic Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration.

Sub-Investigator , June 2004—Present

 

FVF2598g:  A Phase III, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of rhuFab V2 (ranibizumab) in Subjects with Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration.  Sub-Investigator, June 2003—Present.

 

FVF2587g:  A Phase III, Multicenter, Randomized, Double-Masked, Active Treatment–Controlled Study of the Efficacy and Safety of rhuFab V2 [Ranibizumab] Compared To Verteporfin (Visudyne) Photodynamic Therapy In Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration.  Sub-Investigator,  September 2003—Present.

 

A Multicenter, Double-Masked, Study of the Safety and Efficacy of TRAVATAN BAC-free Compared to TRAVATAN in patients with Open-Angle Glaucoma or Ocular Hypertension

 

A Study of the Safety and Efficacy of Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution Compared to Xalatan ® and Timolol 0.5% Dosed Concomitantly in Patients with Open-Angle glaucoma or Ocular Hypertension

 

A 5-Day, Multicenter, Double-Masked, Randomized, Paired-Eye Comparison, Active-Controlled Study of the Safety and Efficacy of bimatoprost 0.01%. bimatoprost 0.015% With EDTA, bimatoprost 0.015%, and bimatoprost 0.02% Once Daily Compared with  Lumigan® (bimatoprost 0.03%) Ophthalmic Solution Once Daily in Patients with Glaucoma or Ocular Hypertension

 

A Study to Evaluate the Clinical and Microbial Efficacy and Safety of 1.0% Azasite™ Compared to Vehicle in the Treatment of Bacterial Conjunctivitis

 

A Randomized, Double-Masked, Parallel-Group, Multicenter, 12-Month Trial Comparing the Efficacy and Safety of Tafluprost 0.0015% with Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension

 

A Multicenter, Double-Masked,, Randomized, Parallel, Three-Week Study of the Safety and Efficacy of  Bimatoprost 0.03%/Timolol 0.5% Combination Ophthalmic Solution Once Daily, Bimatoprost 0.03% Once Daily and Timolol 0.5% Twice Daily Ophthalmic Solution  Dosed Concurrently, and Bimatoprost 0.03% Once Daily Ophthalmic Solution in Treatment Naïve Patients with Glaucoma or Ocular Hypertension